Y0001112

Gestodene

European Pharmacopoeia (EP) Reference Standard

Synonym(s):
SHB 331, (17α)-13-Ethyl-17-hydroxy-18,19-Dinorpregna-4,15-dien-20-yn-3-one, WL 70, Gestinol
Empirical Formula (Hill Notation):
C21H26O2
CAS Number:
Molecular Weight:
310.43
MDL number:
PubChem Substance ID:
NACRES:
NA.24
Pricing and availability is not currently available.

grade

pharmaceutical primary standard

form

neat

CofA

certificate is enclosed in each package

mfr. no.

EDQM

Featured Industry

Pharmaceutical (small molecule)

format

neat

SMILES string

CCC@12CCC@H3C@@H(CCC4=CC(=O)CCC@H34)C@@H1C=CC@@2(O)C#C

InChI

1S/C21H26O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,10,12-13,16-19,23H,3,5-9,11H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1

InChI key

SIGSPDASOTUPFS-XUDSTZEESA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Biochem/physiol Actions

Gestodene is a synthetic progestin used as a contraceptive. Gestodene displays a high binding affinity to the progesterone receptor, and also binds strongly to adrogen and glucocorticoid receptors.

Packaging

Unit quantity: 130 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference subtance catalogue.

Caution

Other Notes

Sales restrictions may apply.

Pictograms

Health hazard

Signal Word

Warning

Hazard Statements

Precautionary Statements

RIDADR

NONH for all modes of transport

WGK Germany

WGK 3

Certificate of Analysis
Certificate of Origin
Hormone-based contraceptive therapy and risk of venous thromboembolism in young women.
Helen Roberts
Clinical advances in hematology & oncology : H&O, 8(5), 307-309 (2010-06-17)
Ladakan Jaithitivit et al.
Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 95(5), 630-635 (2012-09-22)
To determine cycle control, safety, and acceptability of a 24-day oral contraceptive regimen containing 15 micrograms of ethinylestradiol and 60 micrograms of gestodene. This was an open-label, non-comparative study. Healthy women 18 to 35 years old who attended the Family...
Sopon Cheewadhanaraks et al.
Gynecologic and obstetric investigation, 74(2), 151-156 (2012-06-23)
To evaluate the efficacy and tolerability of postoperative depot medroxyprogesterone acetate (DMPA) versus postoperative continuous oral contraceptive (OC) pills in the treatment of endometriosis-associated pain. After a conservative surgery, 84 patients with symptomatic endometriosis were randomized to receive either intramuscular...
Romana Dmitrovic et al.
Obstetrics and gynecology, 119(6), 1143-1150 (2012-05-24)
To estimate whether continuous oral contraceptive pills (OCPs) will result in more pain relief in primary dysmenorrhea patients than cyclic OCPs, which induce withdrawal bleeding with associated pain and symptoms. We conducted a double-blind, randomized, controlled trial comparing continuous to...
Øjvind Lidegaard et al.
BMJ (Clinical research ed.), 343, d6423-d6423 (2011-10-27)
To assess the risk of venous thromboembolism from use of combined oral contraceptives according to progestogen type and oestrogen dose. National historical registry based cohort study. Four registries in Denmark. Non-pregnant Danish women aged 15-49 with no history of thrombotic...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.